Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Leber

Showing results (111-120 of 125) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|March 19, 2016
Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective studyRena Buckstein, Richard A Wells, Nancy Zhu, et al.
Leukemia|December 19, 2023
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasmsTracy Murphy, Jacqueline M Mason, Brian Leber, et al.
British Journal of Haematology|June 1, 2021
Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN studyIrina Amitai, Michelle Geddes, Nancy Zhu, et al.
British Journal of Haematology|July 6, 2017
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysisHeather A Leitch, Ambica Parmar, Richard A Wells, et al.
Cell|May 29, 2012
Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cellsEleftherios Sachlos, Ruth M Risueño, Sarah Laronde, et al.
Haematologica|August 18, 2022
High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromesJennifer Teichman, Michelle Geddes, Nancy Zhu, et al.
Haematologica|July 10, 2025
Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemiaTracy Murphy, Boyang Zhang, Tong Zhang, et al.
American Journal of Hematology|February 12, 2024
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemiaKeith W Pratz, Brian A Jonas, Vinod Pullarkat, et al.
Leukemia & Lymphoma|November 9, 2024
Improvement in quality of life in MDS patients who become transfusion independent after treatmentBo A Wan, Shabbir M H Alibhai, Lisa Chodirker, et al.
Leukemia|August 29, 2020
Revised 15-item MDS-specific frailty scale maintains prognostic potentialBo A Wan, Aziz Nazha, Rebecca Starkman, et al.
Pageof 13

Showing results (111-120 of 125) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|March 19, 2016
Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective studyRena Buckstein, Richard A Wells, Nancy Zhu, et al.
Leukemia|December 19, 2023
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasmsTracy Murphy, Jacqueline M Mason, Brian Leber, et al.
British Journal of Haematology|June 1, 2021
Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN studyIrina Amitai, Michelle Geddes, Nancy Zhu, et al.
British Journal of Haematology|July 6, 2017
Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysisHeather A Leitch, Ambica Parmar, Richard A Wells, et al.
Cell|May 29, 2012
Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cellsEleftherios Sachlos, Ruth M Risueño, Sarah Laronde, et al.
Haematologica|August 18, 2022
High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromesJennifer Teichman, Michelle Geddes, Nancy Zhu, et al.
Haematologica|July 10, 2025
Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemiaTracy Murphy, Boyang Zhang, Tong Zhang, et al.
American Journal of Hematology|February 12, 2024
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemiaKeith W Pratz, Brian A Jonas, Vinod Pullarkat, et al.
Leukemia & Lymphoma|November 9, 2024
Improvement in quality of life in MDS patients who become transfusion independent after treatmentBo A Wan, Shabbir M H Alibhai, Lisa Chodirker, et al.
Leukemia|August 29, 2020
Revised 15-item MDS-specific frailty scale maintains prognostic potentialBo A Wan, Aziz Nazha, Rebecca Starkman, et al.
Pageof 13